CTLA4 and cancer: It should be noted that, recently, cancer therapy has made a quantum leap using immunological methods, such as anti-CTLA4 12 and anti-PD-1/PD-L1 monoclonal antibodies that inactivate negative regulators or checkpoints of the adaptive immune system [9].